Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial

BACKGROUND: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial(1) prospectively obtained serum and tumor core biopsies and randomized 255 chemorefractory non–small-cell lung cancer (NSCLC) patients into four phase II trials: erlotinib, erlotinib-bexarotene, van...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Thorac Oncol
Autors principals: Tsao, Anne S., Liu, Suyu, Lee, J. Jack, Alden, Christine M., Blumenschein, George R., Herbst, Roy, Davis, Suzanne E., Kim, Edward, Lippman, Scott, Heymach, John, Tran, Hai, Tang, XiMing, Wistuba, Ignacio, Hong, Waun Ki
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5118909/
https://ncbi.nlm.nih.gov/pubmed/23584298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31828d08ae
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars